Navigation Links
Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
Date:3/13/2009

NEW YORK, March 13 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research seeks applications from industry researchers under its $5-million Therapeutics Development Initiative (TDI). The Foundation also announced that, going forward, TDI will be launched bi-annually. Applications will be accepted twice a year, with up to $2.5 million in funding available each spring and another $2.5 million available in the fall.

First launched in 2006, TDI is designed exclusively to support and bolster industry-focused efforts on Parkinson's research as part of MJFF's focus on 'de-risking' preclinical PD research for biotech and pharmaceutical companies -- thus expanding and catalyzing industry investments in Parkinson's drug development. By adding MJFF resources to companies' own, the Foundation aims to make Parkinson's therapies a more attractive bet and help to push research further along the pipeline.

Years of basic research in cell-based studies and animal models have uncovered numerous promising biological targets that show initial promise to impact the symptoms and progression of Parkinson's disease. But translating these fundamental discoveries into practical treatments requires focused and concerted effort to identify and optimize realistic strategies for eventual human testing.

Under the 2009 TDI program, MJFF primarily seeks to support pre-clinical development of Parkinson's disease therapies that have the potential for fundamentally altering disease course and/or improving treatment of symptoms above and beyond current standards of care. Proposals must focus on key and critical pre-clinical studies necessary for developing, optimizing and evaluating therapeutic strategies that, if successful, can move into human testing.

The first three years of TDI were enthusiastically received by industry researchers. To date the Foundation has awarded nearly $12.8 million total under the initiative for 24 industry-led projects.

About The Michael J. Fox Foundation

The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease through an aggressively funded research agenda. To date, the Foundation has funded nearly $140 million in research directly or through partnerships.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Gene Network Sciences Announces Michael Gilman as Board Member
2. Nyenrode Honorary Doctorate for Professor Michael E. Porter
3. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
4. Biotechnology Veteran Michael Webb Joins Boston-based Investment Bank as Senior Advisor
5. BioNanomatrix Appoints Michael Kochersperger as Vice President of Engineering
6. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
7. You: Being Beautiful Authors Mehmet Oz, MD, & Michael Roizen, MD, Call Ribose One of the Decades Real Nutritional Heroes
8. Xceleron Names Michael Butler as President & CEO
9. LCA-Vision Names Michael J. Celebrezze CFO
10. Wyeth Names Michael Kamarck President, Technical Operations & Product Supply
11. Trusted LASIK Surgeons Welcomes LASIK Expert Michael Raizman of Boston to its Unique LASIK Directory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Morrisville, NC (PRWEB) , ... January 16, 2017 ... ... science company, received the prestigious Tibbetts Award from the U.S. Small Business ... participants “that have created a significant economic or social impact […] and are considered ...
(Date:1/13/2017)... Research and Markets has announced the addition of the "Biosimilars ... report to their offering. ... The biosimilars market is expected to reach USD 10.90 ... CAGR of 26.3%. The global biosimilars market is ... such as rising incidence of various diseases, increasing demand for biosimilar ...
(Date:1/13/2017)... ... January 13, 2017 , ... ... companies to offer its customers three new solutions for measurements where traditional cuvette ... handy if a customer has an oddly-shaped sample that would not fit into ...
(Date:1/12/2017)... ... ... Huffman Engineering, Inc. , a leader in control systems integration, today ... office as a chemical engineer. In his new role, Beck will use his ... science manufacturing and water/wastewater industries. , Prior to joining Huffman Engineering, Beck served for ...
Breaking Biology Technology:
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. ... has priced an offering of €500.0 million principal amount of ... principal amount of its 2.425% senior unsecured notes due 2026. ... to occur on December 13, 2016, subject to the satisfaction of ... annual basis. The Company intends ...
(Date:12/6/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, and the ... five (5) year funding commitment by Securus to ... rehabilitation and reentry support to more inmates and ... 2004, the Prison Entrepreneurship Program (PEP) is an ...
(Date:12/2/2016)... , December 1, 2016 ... (Fingerprint, Voice), Future Technology (Iris Recognition System), Vehicle ... - Global Forecast to 2021", published by MarketsandMarkets, ... Million in 2016, and is projected to grow ... CAGR of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
Breaking Biology News(10 mins):